Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dy...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

fpak Feb. 23 at 2:37 PM

$SRPT Why are we not moving? Closed today?

0 · Reply

fpak Feb. 23 at 2:32 PM

$SRPT Time to fly!

0 · Reply

christineee123 Feb. 23 at 2:23 PM

$SRPT When the crowd is exhausted and bored, that’s often when positioning quietly flips. SRPT feels like it’s transitioning from “dump it” to “wait… maybe.”

0 · Reply

free2dream Feb. 23 at 2:19 PM

$SRPT they need to stop pumping the $SMH for the $XBI to start catching up. $SOX $SMH major bubble , rest of the market is already in correction.

0 · Reply

D1X Feb. 23 at 1:36 PM

$SRPT if Roche doesn’t make a move another BP will.

1 · Reply

D1X Feb. 23 at 1:29 PM

$GILD $SRPT like I’ve stated m&a has been hot since 2025. This could literally see $80+ in no time.

0 · Reply

Pharmer23 Feb. 23 at 12:45 PM

$SRPT big buyout today by $GILD shows how undervalued this damn thing is

0 · Reply

Carlza Feb. 23 at 12:11 PM

$SRPT Warnings coming up. If revenue momentum and guidance hold, this valuation starts looking… compressed.

0 · Reply

kellymone2 Feb. 23 at 10:56 AM

$SRPT Which are your expectations here? Is it underpriced?

1 · Reply

Alzdoc Feb. 23 at 10:21 AM

$SRPT For earning conference i want hear something related to the followings:

1 · Reply

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 8:30 AM EST - 19 days ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Jan 26, 2026, 1:32 PM EST - 27 days ago

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Jan 26, 2026, 8:53 AM EST - 4 weeks ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:10 AM EST - 4 weeks ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:00 AM EST - 4 weeks ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 23, 2026, 4:05 PM EST - 4 weeks ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 16, 2026, 9:25 AM EST - 5 weeks ago

Sarepta Therapeutics: Is Elevidys A Bust?

Jan 12, 2026, 2:36 PM EST - 5 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 11:58 AM EST - 5 weeks ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 9:30 AM EST - 6 weeks ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 7, 2026, 8:30 AM EST - 6 weeks ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 5, 2026, 8:30 AM EST - 7 weeks ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 31, 2025, 5:20 PM EST - 7 weeks ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2025, 6:48 AM EST - 2 months ago

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Dec 11, 2025, 7:00 AM EST - 2 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Nov 25, 2025, 12:07 PM EST - 3 months ago

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Nov 25, 2025, 8:57 AM EST - 3 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Nov 24, 2025, 7:30 AM EST - 3 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 14, 2025, 5:48 PM EST - 3 months ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 2:54 PM EST - 3 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:08 PM EST - 3 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 4, 2025, 1:39 PM EST - 3 months ago

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Nov 4, 2025, 12:33 PM EST - 3 months ago

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Nov 4, 2025, 12:11 PM EST - 3 months ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 9:55 AM EST - 3 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 6:20 AM EST - 3 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 5:36 AM EST - 3 months ago

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:27 AM EST - 3 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 3, 2025, 6:26 PM EST - 3 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 4:24 PM EST - 3 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:05 PM EST - 3 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Oct 27, 2025, 4:05 PM EDT - 4 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 23, 2025, 6:46 AM EDT - 4 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 10, 2025, 11:49 AM EDT - 4 months ago

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

Oct 8, 2025, 11:19 AM EDT - 4 months ago

What's Going On Sarepta Stock On Wednesday?

Oct 3, 2025, 8:30 AM EDT - 5 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sep 5, 2025, 9:00 AM EDT - 6 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Aug 28, 2025, 6:20 AM EDT - 6 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

Aug 25, 2025, 3:11 AM EDT - 6 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 23, 2025, 7:08 AM EDT - 6 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 22, 2025, 12:12 PM EDT - 6 months ago

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

Aug 22, 2025, 9:50 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 21, 2025, 7:00 AM EDT - 6 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

Aug 20, 2025, 3:30 PM EDT - 6 months ago

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

fpak Feb. 23 at 2:37 PM

$SRPT Why are we not moving? Closed today?

0 · Reply

fpak Feb. 23 at 2:32 PM

$SRPT Time to fly!

0 · Reply

christineee123 Feb. 23 at 2:23 PM

$SRPT When the crowd is exhausted and bored, that’s often when positioning quietly flips. SRPT feels like it’s transitioning from “dump it” to “wait… maybe.”

0 · Reply

free2dream Feb. 23 at 2:19 PM

$SRPT they need to stop pumping the $SMH for the $XBI to start catching up. $SOX $SMH major bubble , rest of the market is already in correction.

0 · Reply

D1X Feb. 23 at 1:36 PM

$SRPT if Roche doesn’t make a move another BP will.

1 · Reply

D1X Feb. 23 at 1:29 PM

$GILD $SRPT like I’ve stated m&a has been hot since 2025. This could literally see $80+ in no time.

0 · Reply

Pharmer23 Feb. 23 at 12:45 PM

$SRPT big buyout today by $GILD shows how undervalued this damn thing is

0 · Reply

Carlza Feb. 23 at 12:11 PM

$SRPT Warnings coming up. If revenue momentum and guidance hold, this valuation starts looking… compressed.

0 · Reply

kellymone2 Feb. 23 at 10:56 AM

$SRPT Which are your expectations here? Is it underpriced?

1 · Reply

Alzdoc Feb. 23 at 10:21 AM

$SRPT For earning conference i want hear something related to the followings:

1 · Reply

Alzdoc Feb. 23 at 10:16 AM

$SRPT Pipeline Readouts (The "Hidden" Value) Sarepta is moving into siRNA (silencing bad genes) rather than just adding new ones. • SRP-1003 (Myotonic Dystrophy): They hit a milestone recently that paid their partner $200M. Look for any "early data" hints. • Limb-Girdle Muscular Dystrophy (LGMD): This is their next big gene therapy launch. Updates on filing for FDA approval in mid-2026 could be a massive stock mover.

1 · Reply

Maxxinne Feb. 23 at 10:14 AM

$SRPT The chart today looked like someone was slowly scooping shares all afternoon. Not hype. Not chaos. Just quiet strength. That’s usually how reversals start.

0 · Reply

Alzdoc Feb. 23 at 10:12 AM

$SRPT Pipeline Momentum: The siRNA "Engine" Sarepta is pivoting away from just being a "Duchenne company." Analysts from Jefferies recently estimated a $1 billion market opportunity for each of their new siRNA programs. • SRP-1001 (FSHD) & SRP-1003 (DM1): Initial Phase 1/2 data for these muscular dystrophy treatments are expected in Q1 2026. Any positive data shared during Wednesday's call could cause a significant swing in the stock price. • Manufacturing Efficiency: Expect updates on how AI-guided capsid engineering is lowering their "Cost of Goods Sold" (COGS), a major concern for expensive gene therapies.

0 · Reply

Alzdoc Feb. 23 at 10:01 AM

$SRPT AI-Guided Capsid Engineering One of the biggest hurdles in gene therapy is the "delivery truck"—the viral vector (usually AAV) that carries the healthy gene into the body. Sarepta uses AI-guided engineering to design next-generation capsids. • The Goal: To create vectors that are more efficient at reaching target tissues (like muscle or the brain) while avoiding the immune system. • The Benefit: Higher efficiency allows for lower doses, which reduces the risk of side effects and lowers manufacturing costs. i can see the future sucess of SRPT!

1 · Reply

Andreah3 Feb. 23 at 9:55 AM

$SRPT Under $2B market cap for a company with a commercial gene therapy on market still feels disconnected from reality. Volatile? Yes. Broken? No.

0 · Reply

BioRich Feb. 23 at 3:57 AM

$SRPT Look for FDA news that will help $SRPT and $CAPR tomorrow/this week. Also, $DYN recently on my radar, but haven't dug into it yet. Anyone have pro's/con's for $DYN? Cheers!

0 · Reply

StocksCryptoNews Feb. 23 at 3:50 AM

$SRPT Sarepta Therapeutics Expected to Announce Quarterly Earnings on Wednesday https://www.marketbeat.com/instant-alerts/sarepta-therapeutics-srpt-expected-to-announce-quarterly-earnings-on-wednesday-2026-02-18/#google_vignette

0 · Reply

NickBFinanc Feb. 23 at 3:29 AM

$SRPT Sarepta’s SRP-1005 Trial Approval Opens New Huntington’s Disease Opportunity https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sareptas-srp-1005-trial-approval-opens-new-huntingtons-disea

0 · Reply

Thaigrlsrk Feb. 22 at 11:45 PM

$SRPT Put in my 2 cents for the call. Was told nicely thank you. Fingers crossed.

1 · Reply

MartinaGutierrez Feb. 22 at 5:27 PM

$SRPT Japan just got Elevidys and it's the country’s first regenerative therapy for DMD. From Sarepta to Roche / Chugai Pharmaceutical, the Asia expansion is officially underway. Fingers crossed this gives Sarepta even more lift heading into 2026. https://www.chugai-pharm.co.jp/english/news/detail/20260220113000_1229.html

0 · Reply

PressureBusspipe Feb. 22 at 1:11 PM

$SRPT buying

0 · Reply

txctjeb1 Feb. 22 at 12:49 AM

$SRPT The patent for cultured host cells expired November 12, 2022. Sarepta Therapeutics’ Elevidys received its first FDA approval on June 22, 2023. Since Serepta did not earn any revenue prior to the expiration of the patent, on what basis could they be sued for damages by Regenxbio? Regenxbio has requested more than $900 million in damages in the case.

2 · Reply

Market Cap	1.98B
Revenue (ttm)	1.90B
Net Income (ttm)	235.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	6.86
Profit Margin	12.37%
Debt to Equity Ratio	0.78

Volume	1,493,900
Avg Vol	2,771,258
Day's Range	N/A - N/A
Shares Out	104.79M
Stochastic %K	96%
Beta	0.39
Analysts	Sell
Price Target	$21.43